Sung-Yong Oh

15PUBLICATIONS
89CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersRural and remote health servicesApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Occupational epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Mar 12, 2025
Efficacy of combined CD38 and PD-1 inhibition with isatuximab and cemiplimab for relapsed/refractory NK/T-cell lymphoma.

Seok Jin Kim, Jing Quan Lim, Sang Eun Yoon

|Mar 11, 2025
Comprehensive clinico-genetic analysis reveals prognostic factors of blastic plasmacytoid dendritic cell neoplasm.

Ji Hyun Lee, Sung-Yong Oh, Taek Gyu Lee

|Oct 18, 2024
Phase 2 trial of avelumab in combination with gemcitabine in advanced leiomyosarcoma as a second-line treatment (EAGLES, Korean Cancer Study Group UN18-09).

Miso Kim, Yu Jung Kim, Koung Jin Suh

|Sep 07, 2023
Community Care for Cancer Patients in Rural Areas: An Integrated Regional Cancer Center and Public Health Center Partnership Model.

Jung Hun Kang, Chang Yoon Jung, Ki-Soo Park

|Jul 27, 2022
Changes of Immune Cell Fractions in Patients Treated with Immune Checkpoint Inhibitors.

Hye Ryeon Kim, Jung Hun Kang, Sung Hyun Kim

|Apr 23, 2022
Modified FOLFIRINOX as a Second-Line Treatment for Patients with Gemcitabine-Failed Advanced Biliary Tract Cancer: A Prospective Multicenter Phase II Study.

Yong-Pyo Lee, Sung Yong Oh, Kwang Min Kim

Pageof 3

Frequent Collaborators

3 joint publications

Jung Hun Kang

3 joint publications

Seok-Goo Cho

2 joint publications

Jae Wook Lee

2 joint publications

Hoon Kook